Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nyse  >  Edwards Lifesciences Corporation    EW

EDWARDS LIFESCIENCES CORPORATION

(EW)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies
The feature you requested does not exist. However, we suggest the following feature:

Edwards Lifesciences : Northwestern University and Edwards Lifesciences Catastrophic Failure to Heed Minneapolis FDA Warnings in 2018

share with twitter share with LinkedIn share with facebook
08/10/2020 | 04:38am EDT

Sheboygan, WI, In August 2020, Senior Leadership at one of Chicago's top Universities, Northwestern in Evanston and Chicago, failed to heed Federal Food and Drug Administration warnings to stop experimental heart surgeries over the past decade. Injuries reported to the FDA during a meeting at the Minneapolis District office in December 2018, could have been prevented had the University heeded the FDA warning in 2008.

As of May 2020, there are now over 1000 patients who underwent the experimental research surgery and there is no path to justice to inform patients and doctors of the risk, until the University follows their own Federal Assurance policy to protect patients, policy number 1549, and the FDA follows their own regulations to protect patients in the United States of America.

In 2018, another discovery of the use of an undisclosed device in patients was revealed to the FDA during a meeting held in the Minneapolis District office with victims and their families. During the meeting, the FDA learned of a third device developed by Edwards Lifesciences the Model 1155 caliper measurement tool.

Ten years since the last FDA investigation of Northwestern University, several more victims discovered they were injured by the experimental heart surgery technique to measure their heart valve leaflets. The FDA agreed to a meeting at the Minneapolis District office, after the local press showed up for a press conference in the lobby of the FDA in Minneapolis.

This branch of the FDA is important in the medical device regulation. The patients and their family members, attended a meeting in the Minneapolis FDA for over 3 hours testified to the danger of the experimental surgery, their injuries, and their ongoing complications as related to the devices invented by the heart surgeon and manufactured by Edwards Lifesciences, to develop novel heart valve rings and a novel measurement technique to "size a heart valve."

The patients injuries range from reoperations, severe heart attacks, stroke and death, as published by Northwestern University's own Student Newspaper the Daily Northwestern.

https://dailynorthwestern.com/2019/05/23/top-stories/years-after-surgery-documents-renew-patients-malpractice-claims-northwestern-memorial-doctor/#

Dr. Rajamannan awaits final decision from the FDA to inform the now 1000 patients affected.

https://www.linkedin.com/pulse/northwestern-university-edwards-lifesciences-failure-heed-rajamannan/?trackingId=n0w0PWOtQbTZaBfbkHkVzg==

https://www.youtube.com/watch?v=SPfj1SzCw58

Distributed by https://pressat.co.uk/

.

(C) 2020 M2 COMMUNICATIONS, source M2 PressWIRE

share with twitter share with LinkedIn share with facebook
Latest news on EDWARDS LIFESCIENCES CORPO
08/10EDWARDS LIFESCIENCES : Northwestern University and Edwards Lifesciences Catastro..
AQ
07/27EDWARDS LIFESCIENCES : Management's Discussion and Analysis of Financial Conditi..
AQ
07/23EDWARDS LIFESCIENCES CORP : Results of Operations and Financial Condition, Finan..
AQ
07/23EDWARDS LIFESCIENCES : 2Q Earnings Snapshot
AQ
07/23EDWARDS LIFESCIENCES : Reports Second Quarter Results
PR
07/23EDWARDS LIFESCIENCES CORPORATION : Half-year results
CO
07/20EDWARDS LIFESCIENCES CORPORATION : half-yearly earnings release
07/16MENTICE PUBL : receives order of total SEK 7.0 million from Edwards Lifesciences
AQ
07/15EDWARDS LIFESCIENCES : Gets FDA OK for Konect Resilia Aortic Valved Conduit
DJ
07/15EDWARDS LIFESCIENCES CORP : Change in Directors or Principal Officers, Financial..
AQ
More news
Financials (USD)
Sales 2020 4 382 M - -
Net income 2020 827 M - -
Net cash 2020 723 M - -
P/E ratio 2020 57,0x
Yield 2020 -
Capitalization 47 663 M 47 663 M -
EV / Sales 2020 10,7x
EV / Sales 2021 9,10x
Nbr of Employees 13 900
Free-Float 97,4%
Chart EDWARDS LIFESCIENCES CORPORATION
Duration : Period :
Edwards Lifesciences Corporation Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EDWARDS LIFESCIENCES CORPO
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Average target price 84,17 $
Last Close Price 76,66 $
Spread / Highest target 23,9%
Spread / Average Target 9,80%
Spread / Lowest Target -32,2%
EPS Revisions
Managers
NameTitle
Michael A. Mussallem Chairman & Chief Executive Officer
Scott B. Ullem Chief Financial Officer & Vice President
John P. McGrath Vice President-Quality, Regulatory & Clinical
Todd J. Brinton Chief Scientific Officer & VP-Advanced Technology
William J. Link Independent Director
Sector and Competitors